PT  - JOURNAL ARTICLE
AU  - Han, Alvin X.
AU  - Kozanli, Eva
AU  - Koopsen, Jelle
AU  - Vennema, Harry
AU  - ,
AU  - Hajji, Karim
AU  - Kroneman, Annelies
AU  - van Walle, Ivo
AU  - Klinkenberg, Don
AU  - Wallinga, Jacco
AU  - Russell, Colin A.
AU  - Eggink, Dirk
AU  - Reusken, Chantal B.E.M.
TI  - Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands
AID  - 10.1101/2022.03.21.22272611
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.21.22272611
4099  - http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272611.short
4100  - http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272611.full
AB  - Variants of concern (VOCs) of SARS-CoV-2 have caused resurging waves of infections worldwide. In the Netherlands, Alpha, Beta, Gamma and Delta variants circulated widely between September 2020 and August 2021. To understand how various control measures had impacted the spread of these VOCs, we analyzed 39,844 SARS-CoV-2 genomes collected under the Dutch national surveillance program. We found that all four VOCs were introduced before targeted flight restrictions were imposed on countries where the VOCs first emerged. Importantly, foreign introductions, predominantly from other European countries, continued during these restrictions. Our findings show that flight restrictions had limited effectiveness in deterring VOC introductions due to the strength of regional land travel importation risks. We also found that the Alpha and Delta variants largely circulated more populous regions with international connections after their respective introduction before asymmetric bidirectional transmissions occurred with the rest of the country and the variant dominated infections in the Netherlands. As countries consider scaling down SARS-CoV-2 surveillance efforts in the post-crisis phase of the pandemic, our results highlight that robust surveillance in regions of early spread is important for providing timely information for variant detection and outbreak control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAXH and CAR were supported by ERC NaviFlu (no. 818353). C.A.R. was also supported by NIH R01 (5R01AI132362-04) and an NWO Vici Award (09150182010027).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise at the National Institute for Public Health and the Environment (RIVM) assessed the research proposal following the specific conditions as stated in the law for medical research involving human subjects. The work described was exempted for further approval by the ethical research committee. Pathogen surveillance is a legal task of the RIVM and is carried out under the responsibility of the Dutch Minister of Health, Welfare and Sports. The Public Health Act (Wet Publieke Gezondheid) provides that RIVM may receive pseudonymized data for this task without informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll codes for our analyses are available at https://github.com/AMC-LAEB/nl_sars-cov-2_genomic_epi_2022. https://github.com/AMC-LAEB/nl_sars-cov-2_genomic_epi_2022